The transmembrane tyrosine kinase receptor HER2 is overexpressed in approximately 20% of breast cancers.222 Trastuzumab is a monoclonal antibody against HER2 and improves survival in patients with HER2 positive breast cancer. Here, ERBB2 is linked to breast carcinoma.